-
1
-
-
0035041926
-
Antipsychotic-induced weight gain: A review of the literature
-
Allison DB, Casey DE. Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry. 2001 ; 62 (suppl 7). 22-31 (Pubitemid 32402182)
-
(2001)
Journal of Clinical Psychiatry
, vol.62
, Issue.SUPPL. 7
, pp. 22-31
-
-
Allison, D.B.1
Casey, D.E.2
-
2
-
-
0038402737
-
Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: Results of the EIRE study
-
DOI 10.1016/S0920-9964(02)00431-0
-
Bobes J, Rejas J, Garcia-Garcia M, et al. Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study. Schizophr Res. 2003 ; 62: 77-88 (Pubitemid 36588706)
-
(2003)
Schizophrenia Research
, vol.62
, Issue.1-2
, pp. 77-88
-
-
Bobes, J.1
Rejas, J.2
Garcia-Garcia, M.3
Rico-Villademoros, F.4
Garcia-Portilla, M.P.5
Fernandez, I.6
Hernandez, G.7
-
3
-
-
60949099657
-
Antipsychotic-induced body weight gain: Predictors and a systematic categorization of the long-term weight course
-
Gebhardt S, Haberhausen M, Heinzel-Gutenbrunner M, et al. Antipsychotic-induced body weight gain: predictors and a systematic categorization of the long-term weight course. J Psychiatr Res. 2009 ; 43: 620-626
-
(2009)
J Psychiatr Res
, vol.43
, pp. 620-626
-
-
Gebhardt, S.1
Haberhausen, M.2
Heinzel-Gutenbrunner, M.3
-
4
-
-
0035108241
-
Long-term olanzapine treatment: Weight change and weight-related health factors in schizophrenia
-
Kinon BJ, Basson BR, Gilmore JA, Tollefson GD. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J Clin Psychiatry. 2001 ; 62: 92-100 (Pubitemid 32199865)
-
(2001)
Journal of Clinical Psychiatry
, vol.62
, Issue.2
, pp. 92-100
-
-
Kinon, B.J.1
Basson, B.R.2
Gilmore, J.A.3
Tollefson, G.D.4
-
5
-
-
25144456112
-
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia
-
DOI 10.1056/NEJMoa051688
-
Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005 ; 353: 1209-1223 (Pubitemid 41345943)
-
(2005)
New England Journal of Medicine
, vol.353
, Issue.12
, pp. 1209-1223
-
-
Lieberman, J.A.1
Scott Stroup, T.2
McEvoy, J.P.3
Swartz, M.S.4
Rosenheck, R.A.5
Perkins, D.O.6
Keefe, R.S.E.7
Davis, S.M.8
Davis, C.E.9
Lebowitz, B.D.10
Severe, J.11
Hsiao, J.K.12
-
6
-
-
34547218869
-
Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: A randomized, double-blind 52-week comparison
-
DOI 10.1176/appi.ajp.164.7.1050
-
McEvoy JP, Lieberman JA, Perkins DO, et al. Efficacy and tolerability of olanzapine, quetiapine and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry. 2007 ; 164: 1050-1060 (Pubitemid 47121394)
-
(2007)
American Journal of Psychiatry
, vol.164
, Issue.7
, pp. 1050-1060
-
-
McEvoy, J.P.1
Lieberman, J.A.2
Perkins, D.O.3
Hamer, R.M.4
Gu, H.5
Lazarus, A.6
Sweitzer, D.7
Olexy, C.8
Weiden, P.9
Strakowski, S.D.10
-
7
-
-
79955399654
-
Metabolic parameters in patients treated with olanzapine or other atypical antipsychotics (abstract)
-
Osuntokun O, Millen B, Xu I, et al. Metabolic parameters in patients treated with olanzapine or other atypical antipsychotics (abstract). Schizophr Res. 2008 ; 102 (suppl 2). 243-243
-
(2008)
Schizophr Res
, vol.102
, Issue.SUPPL. 2
, pp. 243-243
-
-
Osuntokun, O.1
Millen, B.2
Xu, I.3
-
8
-
-
37049034235
-
A 12-week randomized clinical trial to evaluate metabolic changes in drug-naive, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone
-
Perez-Iglesias R, Crespo-Facorro B, Amado JA, et al. A 12-week randomized clinical trial to evaluate metabolic changes in drug-naïve, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone. J Clin Psychiatry. 2007 ; 68: 1733-1740 (Pubitemid 350247503)
-
(2007)
Journal of Clinical Psychiatry
, vol.68
, Issue.11
, pp. 1733-1740
-
-
Perez-Iglesias, R.1
Crespo-Facorro, B.2
Amado, J.A.3
Garcia-Unzueta, M.T.4
Ramirez-Bonilla, M.L.5
Gonzalez-Blanch, C.6
Martinez-Garcia, O.7
Vazquez-Barquero, J.L.8
-
9
-
-
58249129947
-
Glucose and lipid disturbances after 1 year of antipsychotic treatment in a drug-naïve population
-
Perez-Iglesias R, Mata I, Pelayo-Teran JM, et al. Glucose and lipid disturbances after 1 year of antipsychotic treatment in a drug-naïve population. Schizophr Res. 2009 ; 107: 115-121
-
(2009)
Schizophr Res
, vol.107
, pp. 115-121
-
-
Perez-Iglesias, R.1
Mata, I.2
Pelayo-Teran, J.M.3
-
10
-
-
0037708783
-
The implications of weight changes with antipsychotic treatment
-
Sussman N. The implications of weight changes with antipsychotic treatment. J Clin Psychopharmacol. 2003 ; 23 (3 suppl 1). S21 - S26
-
(2003)
J Clin Psychopharmacol
, vol.23
, Issue.3 SUPPL. 1
-
-
Sussman, N.1
-
11
-
-
64749083959
-
Effects of six second generation antipsychotics on body weight and metabolism - Risk assessment and results from a prospective study
-
Tschoner A, Engl J, Rettenbacher M, et al. Effects of six second generation antipsychotics on body weight and metabolism - risk assessment and results from a prospective study. Pharmacopsychiatry. 2009 ; 42: 29-34
-
(2009)
Pharmacopsychiatry
, vol.42
, pp. 29-34
-
-
Tschoner, A.1
Engl, J.2
Rettenbacher, M.3
-
12
-
-
0033037295
-
Novel antipsychotics: Comparison of weight gain liabilities
-
Wirshing DA, Wirshing WC, Kysar L, et al. Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry. 1999 ; 60: 358-363 (Pubitemid 29289721)
-
(1999)
Journal of Clinical Psychiatry
, vol.60
, Issue.6
, pp. 358-363
-
-
Wirshing, D.A.1
Wirshing, W.C.2
Kysar, L.3
Berisford, M.A.4
Goldstein, D.5
Pashdag, J.6
Mintz, J.7
Marder, S.R.8
|